Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $30.50

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $30.50.

Several research firms have recently weighed in on CPRX. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Truist Financial upped their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This represents a 18.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. This represents a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $50,000. Larson Financial Group LLC increased its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the period. CWM LLC lifted its holdings in Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new position in Catalyst Pharmaceuticals in the 2nd quarter worth about $70,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $21.69 on Tuesday. Catalyst Pharmaceuticals has a fifty-two week low of $13.00 and a fifty-two week high of $24.27. The firm has a 50-day moving average of $20.97 and a 200 day moving average of $18.28. The firm has a market cap of $2.59 billion, a P/E ratio of 18.38, a PEG ratio of 3.67 and a beta of 0.75.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.